You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
香雪製藥(300147.SZ):TCR-T和CAR-T都是過繼免疫細胞治療
格隆匯 05-11 15:17

格隆匯5月11日丨香雪製藥(300147.SZ)在互動平台表示,TCR-T和CAR-T都是過繼免疫細胞治療,即從腫瘤患者體內分離免疫細胞,在體外進行基因改造和擴增,然後回輸到患者體內,但它們識別抗原的機制截然不同。CAR-T細胞使用與癌細胞表面特定抗原結合的抗體片段,TCR-T細胞可識別細胞膜表面或細胞內來源的腫瘤特異性抗原,可以靶向大部分的腫瘤特異性抗原,尤其是能識別那些腫瘤細胞內抗原。因此TCR-T細胞治療的靶點範圍更廣,更有潛力衝破實體瘤的堅固防線。 TCR-T的作用機制是向普通T細胞中引入新的基因,使得改造過的T細胞能夠表達有效識別腫瘤細胞的TCR,從而引導T細胞殺死腫瘤細胞。基本治療過程就是從腫瘤患者體內分離免疫活性細胞,在體外進行擴增和功能鑑定,然後向患者回輸,從而達到直接殺傷腫瘤或激發機體的免疫應答殺傷腫瘤細胞的目的。相比於CAR-T,TCR-T有着明顯的優勢:首先,TCR-T可以靶向的靶點不僅包括細胞表面抗原,還包括細胞內部抗原。基於這個原因,TCR-T技術擁有比CAR-T更廣泛的應用,特別在實體瘤領域TCR-T技術擁有着明顯的優勢。其次,相比於CAR-T,TCR-T更容易向實體瘤內部滲透。最後,TCR-T引入的是完全人源化的結構不易引起機體的免疫排斥,抗體產生的概率低,因此安全風險也大大降低。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account